Prospect for anti-HER2 receptor therapy in breast cancer

Anticancer Research

Volumn 26, Issue 1 B, 2006, Pages 463-470

  Brand, Francois Xavier ^a   Ravanel, Nadia ^a   Gauchez, Anne Sophie ^a,b   Pasquier, Dominique ^a   Payan, Raoul ^c   Fagret, Daniel ^b   Mousseau, Mireille ^a,b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIV GRENOBLE ALPES   (France)

^c Clinique Belledonne   (France)

Author keywords

Breast cancer; HER2; Resistance; Review; sHER2; Trastuzumab

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AROMATASE INHIBITOR; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; ETOPOSIDE; GELDANAMYCIN; GELDANAMYCIN PLUS TRASTUZUMAB; GEMCITABINE; HYBRID PROTEIN; INTERLEUKIN 2; METHOTREXATE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG; VINBLASTINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN RECOGNITION; BREAST CANCER; BREAST CARCINOGENESIS; CANCER MODEL; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CELL COMMUNICATION AND CELL CONTACT; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY AUTOMATION; METASTASIS; NONHUMAN; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STANDARDIZATION; SURVIVAL TIME;

EID: 32144453529     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Shih C, Padhy LC, Murray M and Weinberg RA: Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290: 261-264, 1981.
2. King CR, Kraus MH and Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974-976, 1985.
3. Schechter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U et al: The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229: 976-978, 1985.
4. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI et al: The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312: 513-516, 1984.
5. Akiyama T, Sudo C, Ogawara H, Toyoshima K and Yamamoto T: The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232: 1644-1646, 1986.
6. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N et al: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319: 230-234, 1986.
7. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139, 1985.
8. Rubin I and Yarden Y: The basic biology of HER2. Ann Oncol 12 suppl 1: 3-8, 2001.
9. Citri A, Skaria KB and Yarden Y: The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 284: 54-65, 2003.
10. Neve RM, Lane HA and Hynes NE: The role of overexpressed HER2 in transformation. Ann Oncol 12 suppl 1: 9-13, 2001.
11. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J and Baselga J: Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 59: 1196-1201, 1999.
12. Ali SM, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA et al: Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem 48: 1314-1320, 2002.
13. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B et al: Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54: 16-20, 1994.
14. Visco V, Bei R, Moriconi E, Gianni W, Kraus MH and Muraro R: ErbB2 immune response in breast cancer patients with soluble receptor ectodomain. Am J Pathol 156: 1417-1424, 2000.
15. Curcio C, Di Carlo E, Clynes R, Smyth MJ, Boggio K, Quaglino E et al: Nonredundant roles of antibody, cytokines, and perform in the eradication of established Her-2/neu carcinomas. Clin Invest 111: 1161-1170, 2003.
16. Press MF, Cordon-Cardo C and Slamon DJ: Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5: 953-962, 1990.
17. Lohrisch C and Piccart M: An overview of HER2. Semin Oncol 28 suppl 18: 3-11, 2001.
18. Menard S, Casalini P, Campiglio M, Pupa S, Agresti R and Tagliabue E: HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol 12 Suppl 1: 15-19, 2001.
19. Ginestier C, Charafe-Jauffret E, Penault-Llorca F, Geneix J, Adelaide J, Chaffanet M et al: Comparative multimethodological measurement of ERBB2 status in breast cancer. J Pathol 202: 286-298, 2004.
20. Ridolfi RL, Jamehdor MR and Arber JM: HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 13: 866-873, 2000.
21. Symmans WF, Liu J, Knowles DM and Inghirami G: Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. Hum Pathol 26: 210-216, 1995.
22. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S et al: HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101: 9393-9398, 2004.
23. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
24. Ross JS and Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16: 413-428, 1998.
25. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y et al: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894-2904, 1997.
26. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M et al: The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8: 307-325, 2003.
27. Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA et al: Cancer and Leukemia Group B. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 7: 2703-2711, 2001.
28. Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L et al: Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20: 1467-1472, 2002.
29. Baselga J: Is circulating HER-2 more than just a tumor marker? CHn Cancer Res 7: 2605-2607, 2001.
30. Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A et al: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6: 2356-2362, 2000.
31. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737-744, 1996.
32. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800-1808, 2002.
33. Köstler WJ, Schwab B, Singer CF, Neuman R, Rücklinger E, Brodowicz T et al: Monitoring of serum Her-2/neu predicts response and progression-free survival to Trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 10: 1618-1624, 2004.
34. Hait WN: The prognostic and predictive values of ECD-HER-2. Clin Cancer Res 7: 2601-2604, 2001.
35. Hanna WM, Kahn HJ, Pienkowska M, Blondal J, Seth A and Marks A: Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting. Mod Pathol 14: 677-685, 2001.
36. Sias PE, Kotts CE, Vetterlein D, Shepard M and Wong WL: ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. J Immunol Methods 132: 73-80, 1990.
37. Artemov D, Mori N, Ravi R and Bhujwalla ZM: Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 63: 2723-2727, 2003.
38. Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, Zafrani B et al: Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 13: 1238-1243, 2000.
39. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C et al: Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37: 255-263, 1993.
40. Weiner LM: Monoclonal antibody therapy of cancer. Semin Oncol 26(5 suppl 14): 43-51, 1999.
41. Baselga J and Albanell J: Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 12 Suppl 1: S35-41, 2001.
42. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM and Fox JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin®). Semin Oncol 26(4 Suppl 12): 60-70, 1999.
43. Feldman AM, Lorell BH and Reis SE: Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 102: 272-274, 2000.
44. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
45. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659-2671, 1998.
46. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A et al: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587-2595, 2001.
47. Pegram MD: Docetaxel and herceptin: foundation for future strategies. Oncologist 6 Suppl 3: 22-25, 2001.
48. Tedesco KL, Thor AD, Johnson DH, Shyr Y, Blum KA, Goldstein LJ et al: Docetaxel combined with trastuzumab is an active regimen in HER-2 3 + overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 22: 1071-1077, 2004.
49. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B et al: Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21: 2889-2895, 2003.
50. O'shaughnessy J: Gemcitabine and trastuzumab in metastatic breast cancer. Semin Oncol 2 Suppl 3: 22-26, 2003.
51. Sledge GW Jr: Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer. Semin Oncol 2 Suppl 3: 19-21, 2003.
52. Lu Y, Zi X, Zhao Y, Mascarenhas D and Pollak M: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852-1857, 2001.
53. Nahta R, Takahashi T, Ueno NT, Hung MC and Esteva FJ: P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 64: 3981-3986, 2004.
54. Miller KD: The role of ErbB inhibitors in trastuzumab resistance. Oncologist 9 Suppl 3: 16-19, 2004.
55. Albanell J and Baselga J: Unraveling resistance to trastuzumab (Herceptin®): insulin-like growth factor-I receptor, a new suspect. J Natl Cancer Inst 93: 1830-1832, 2001.
56. Mandler R, Kobayashi H, Hinson ER, Brechbiel MW and Waldmann TA: Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res 64: 1460-1467, 2004.
57. Badache A and Hynes NE: A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell 5: 299-301, 2004.
58. Nahta R, Hung MC and Esteva FJ: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64: 2343-2346, 2004.
59. Shi M, Xie Z, Feng J, Sun Y, Yu M, Shen B et al: A recombinant anti-erbB2, scFv-Fc-IL-2 fusion protein retains antigen specificity and cytokine function. Biotechnol Lett 25: 815-819, 2003.
60. Lustgarten J: Anti-Her-2/neu-IL-2 or heregulin-IL-2 fusions proteins redirect non-tumor specific CTL to the tumor site for tumor eradication. Cancer Immunol Immunother 52: 751-760, 2003.
61. Repp R, van Ojik HH, Valerius T, Groenewegen G, Wieland G, Oetzel C et al: Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Br J Cancer 89: 2234-2243, 2003.
62. Jasinska J, Wagner S, Radauer C, Sedivy R, Brodowicz T, Wiltschke C et al: Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Int J Cancer 107: 976-983, 2003.
63. Zhang L, Lau YK, Xia W, Hortobagyi GN and Hung MC: Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res 5: 343-353, 1999.
64. Roh H, Hirose CB, Boswell CB, Pippin JA and Drebin JA: Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents. Surgery 126: 413-421, 1999.